亞寶藥業(600351.SH):公司獨家中藥產品的兒童清咽解熱口服液和忍冬感冒顆粒對治療流感都有很好的臨牀效果
格隆匯12月13日丨亞寶藥業(600351.SH)12月13日在投資者互動平台表示,公司獨家中藥產品的兒童清咽解熱口服液和忍冬感冒顆粒對治療流感都有很好的臨牀效果。尤其是兒清咽用於急性咽炎舒肺熱實證,在抗擊新冠的過程中被國內多個省份作為臨牀推薦用藥,近期在抗流感的過程中也得到了很好的臨牀應用。目前公司正在進行該產品的體外抗菌和抗支原體研究,作為公司規劃的十億元級大單品,將從產品力和營銷力兩個方面促進戰略目標的達成。 另外公司與其他企業合作的“丁桂”牌阿奇黴素幹混懸劑正在治療支原體肺炎一線發揮着良好作用。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.